• Our CiPA Instruments

    Patchliner & SyncroPatch 384PE (CiPA ion channel working group); CardioExcyte 96 (CiPA myocyte working group)

  • CiPA hERG Protocol

    This protocol was used for hERG studies on the Patchliner and SyncroPatch 384PE.

  • HTS CiPA hERG Assay

    Effects of Cisapride using the CiPA hERG protocol on the SyncroPatch 384PE

  • Myocyte & Ion Channel Effects

    Arrhythmic Field potentials in iPSC-derived Cardiomyocytes (CardioExcyte 96) and hERG current inhibition (SyncroPatch 384PE)

  • Gigaseal HTS patch clamp

    CiPA-specified cardiac ion channels recorded at high throughput

  • Gigaseal HTS patch clamp

    High throughput recordings of cardiac ion channels at physiological temperature

  • CardioExcyte 96 screening tool

    CardioExcyte 96 with integrated liquid handling for cardiac safety screening

Cardiomyocytes - "Impedance and EFP recordings of Cor.4U cells using Nanion’s CardioExcyte 96"

Icon CE   CardioExcyte 96 Application Note   logo pdf   (1.3 MB)
Cells were kindly provided by Ncardia.  

 Summary:

Cardiomyocytes derived from human inducedpluripotent stem cells (hiPSCs) are gaining interest in cardiac safety screening. Given their relative abundance, availability, ease of use and standardized production, they are likely to provide a viable alternative to acutely isolated cardiomyocytes to assess the pro-arrythmic potentials of drug candidates. Although automated patch clamp can provide excellent information about the effects of compounds on cardiac ion channels and possible effects on the cardiac action potential, other techniques, such as impedance, also provide crucial and complementary information about complex physiological parameters such as beat rate, amplitude and duration. The CardioExcyte 96 is a new hybrid screening tool combining impedance (cell contractility) and extracellular field potential (EFP) recordings. These measurements are non-invasive, label-free and have a temporal resolution of 1 ms. The recordings are made from cells within a network thus providing a physiologically relevant environment for measuring drug-induced changes in beat parameters. This hybrid technology addresses the lack of easy-to-use high-throughput screening for in-vitro assays, and permits the reliable investigation of short- and long-term pharmacological effects. Here we present data recorded on the CardioExcyte 96 using Cor.4U hiPSCs from Axiogenesis. The effects of the compounds blebbistatin, E4031 and nifedipine on the impedance and EFP signals are shown.

Back to Overview

 

 

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok